Todd A. Huffman
Oprichter bij Padlock Therapeutics, Inc.
Actieve functies van Todd A. Huffman
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Padlock Therapeutics, Inc.
 Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Directeur/Bestuurslid | 01-01-2014 | - |
| Oprichter | 01-01-2014 | - | |
| The University of Virginia School of Medicine | Corporate Officer/Principal | - | - |
Loopbaan van Todd A. Huffman
Eerdere bekende functies van Todd A. Huffman
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
RCT BioVentures
 RCT BioVentures Investment ManagersFinance RCT BioVentures (RCT BioVentures) is a venture capital subsidiary of Research Corporation Technologies Inc founded in 1987. The firm is headquartered in Tucson, Arizona. | Private Equity Analist | 01-01-2007 | 30-03-2010 |
Opleiding van Todd A. Huffman
| University of Virginia | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 4 |
| 2 |
Operationeel
| Private Equity Analyst | 1 |
| Doctorate Degree | 1 |
| Director/Board Member | 1 |
Sectoraal
| Consumer Services | 3 |
| Finance | 2 |
| Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
RCT BioVentures
RCT BioVentures Investment ManagersFinance RCT BioVentures (RCT BioVentures) is a venture capital subsidiary of Research Corporation Technologies Inc founded in 1987. The firm is headquartered in Tucson, Arizona. | Finance |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Beurs
- Insiders
- Todd A. Huffman
- Ervaring
